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Available online 28 September 2016Frontotemporal dementia with parkinsonism linked to chromosome 17q21.2 (FTDP-17) is an autosomal-domi-
nant neurodegenerative disorder. Mutations in the MAPT (microtubule-associated protein tau) gene can cause
FTDP-17, but the underlying pathomechanisms of the disease are still unknown. Induced pluripotent stem
cells (iPSCs) hold great promise to model FTDP-17 as such cells can be differentiated in vitro to the required
cell type. Furthermore, gene-editing approaches allow generating isogenic gene-corrected controls that can be
used as a very speciﬁc control. Here,we report the generation of genetically corrected iPSCs froma pre-symptom-
atic carrier of the R406Wmutation in the MAPT-gene.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource table:ame of stem cell
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resourceNatakarn Nimsanor, Benjamin Schmid, Mikkel Aabech
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emailBenjamin Schmid, bsc@bioneer.dkate archived/stock
dateAugust 2016rigin Human induced pluripotent stem cell line H236 C6
ype of resource Gene-corrected induced pluripotent stem cells; originally
derived from skin ﬁbroblasts of a presymptomatic patient
carrying a mutation that causes frontotemporal dementiaub-type iPSC line
ey transcription
factorsEpisomal plasmids containing hOCT4, hSOX2, hL-MYC,
hKLF4, hLIN28 and shP53 (Addgene plasmids 27077, 27078
and 27080, all a gift from Shinya Yamanaka; Okita et al.
2011). This is an open access article under1. Resource details
Previously, we have generated an induced pluripotent stem cell
(iPSC) line (H236 C6) from a pre-symptomatic, 28-year-oldwoman car-
rying an R406W mutation in microtubule-associated protein tau
(MAPT) gene. Reprogramming was performed by electroporation with
three episomal plasmids encoding hOCT4, hSOX2, hKLF4, hL-MYC, and
hLIN28 (Okita et al. 2011; Takahashi et al. 2007). This cell line, termed
H236 C6, has previously been described (Rasmussen et al. 2016).
We have generated a gene-corrected clone of H236 C6 using CRISPR/
Cas9 technology, where the mutated triplet TGG (tryptophan) was
corrected to thewild-type triplet CGG (arginine) using an ssODN (single
stranded oligodeoxynucleotide) as homologous template (Fig. 1A). We
conﬁrmed by sequencing analysis that themutated triplet was corrected
without further deletions or insertions at the CRISPR cutting site (Fig. 1B).
Finally,weconﬁrmedthatthecellswerestillpluripotentaftergene-correc-
tion (Fig. 1C, D and E) and that they showed anormal karyotype (Fig. 1F).2. Materials and methods
2.1. CRISPR design
Isogenic gene-corrected controls were obtained using the
CRISPRs/Cas9 system in combination with an ssODNs serving asthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of iPSCs. (A) Schematic of the gene editing strategy used to correct the MAPT R406Wmutation in exon 13 using the CRISPR/Cas9 system in combination with an
ssODNas homologous construct. (B) Sequencing result of the original clone shows a heterozygous C N Tmutation (leading to the R406Wmutation; upper panel). After gene correction, the
mutation was no longer present (lower panel). (C) Immunoﬂuorescence staining for the pluripotencymarkers OCT4 (red), TRA1-60 (green) and SSEA4 (green), scale bars = 200 μM. (D)
Quantitative PCR analysis of pluripotency genes from the gene-corrected line and a previously established iPSC control line BIONi010-C compared to ﬁbroblasts (set to 1). (E)
Immunocytochemistry for proteins representative of the three germ layers, Tuj1 (ectoderm), SMA (mesoderm) and AFP (endoderm), after in vitro differentiation by embryoid body
formation, scale bars = 100 μM. (F) Representative karyotype of H236 C6 R406W gene-corrected iPSC (46, XX).
601N. Nimsanor et al. / Stem Cell Research 17 (2016) 600–602homologous template covering the site of the mutation. CRISPRs
targeting exon 13 of the MAPT gene were designed at http://crispr.
mit.edu/. The CRISPRs were generated in a single plasmid (a gift
from Feng Zhang) containing both sgRNA and the Cas9
(pSpCas9(BB)-2A-Puro (PX459); Addgene plasmid #62988) follow-
ing the protocol from Ann Ran (Ran et al. 2013).2.2. Nucleofection
iPSCs were cultured on 100 mm dishes coated with Matrigel (Corning
Bioscience) in E8 medium and detached using Accutase when they
reached adensity of 70–90%. A total of 1.5×106 cellswere co-nucleofected
with 8 μg of the CRISPR/Cas9 plasmid PX459, 2 μg of a the pEasyﬂox I plas-
mid with a pgk\\Neo resistance cassette and 1 μL of 100 μM ssODN usingthe P3 Primary Cell Kit (Lonza) and program CA167 following to the
manufacturer's instructions (Lonza). iPSCs were subsequently transferred
back to a Matrigel-coated 100 mm dish in E8 medium supplemented
with 1:200 diluted Revita cell supplement (Gibco). 24 h post-
nucleofection, cells were subjected to neomycin selection for 4 days
(2 days 100nMand2days 250nM) and allowed to recover for aweek. Re-
sistant colonies were then picked and expanded for genotyping.2.3. Genotyping
DNA for genotypingwas extracted using the FlexiGene Kit (Qiagen).
PCR genotypingwas performed using TEMPase Hot Start DNA Polymer-
ase (Ampliqon) according to the manufacturer's instructions at an an-
nealing temperature of 62 °C. The following screening primers were
Table 1
Antibodies used for immunochemistry.
Antibodies and host species Dilution
Company and catalog
number
Pluripotency Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rabbit anti-NANOG 1:100 Millipore, AB5731
Mouse anti-SSEA4 1:500 BioLegend, 330402
Mouse anti TRA-1-60 1:500 BioLegend, 330602
Mouse anti TRA-1-81 1:500 BioLegend, 330702
In vitro
differentiation
Mouse anti-Smooth muscle
actin (SMA)
1:500 Dako, M0851
Rabbit
anti-Alpha-1-fetoprotein
(AFP)
1:500 Dako, A0008
Mouse anti-Beta-III-tubulin
(TUJ1)
1:500 Sigma-Aldrich, T8660
602 N. Nimsanor et al. / Stem Cell Research 17 (2016) 600–602designed covering the R406Wmutation in theMAPT gene: Exon 13 for-
ward 5′-CTGGTCTTTCTCTGGCACTT-3′ and Exon 13 reverse 5′-
ACCAATTAACCGAACTGCG-3′. The PCR products were digested using
NcoI for 1 h to detect gene-corrected clones (correction of the mutation
leads to loss of NcoI restriction enzyme site). Positive clones were then
sequenced using the forward primer to ensure correction of the
mutation.
2.4. R qRT-PCR analysis of stem cell markers
Total RNAwaspuriﬁed fromH236C6GC iPSCs,ﬁbroblasts and the iPSC
line BIONi010-C (Rasmussen et al. 2014) as a positive control usingRNeasy
mini kit (Qiagen, Hilden, Germany). Conversion to cDNA was performed
with RevertAid First Strand cDNA synthesis kit (Thermo Scientiﬁc, Wal-
tham, MA, USA). qPCR analysis was carried out using the TaqMan primers
GAPDHHs03929097_g1, NANOGHs02387400_g1, OCT4 Hs00999632_g1,
TDGF1 Hs02339497_g1, DMNT3B Hs00171876_m1 and GABRB3
Hs00241459_m1 (Thermo Scientiﬁc, Waltham, MA, USA; International
Stem Cell Banking Initiative). Data was analyzed using the 2−ΔΔCt method
relative to GAPDH with ﬁbroblasts as a reference (set to 1).
2.5. In vitro differentiation
iPSCs were dissociated with EDTA (Gibco) and allowed to form ag-
gregates in non-coated cell culture dishes with E8 medium. On day 2,
the E8 mediumwas changed to E6medium (E6medium= E8medium
without FGF2 and TGF-β1). On day 7, the aggregateswere transferred to
matrigel-coated dishes and medium was switched to differentiation
medium. For mesodermal differentiation: DMEM/F12 containing 10%
FBS, 1% L-glutamine, and 1% non-essential amino acids (all Gibco). For
endodermal differentiation: MCDB131-1 containing 0.5% BSA, 0.1%
pen/strep, 3 μM CHIR99021 (Selleckchem), 100 ng/mL Activin A (Cell
Guidance). For ectodermal differentiation: DMEM/F12 mixed with
neurobasal medium in a ratio of 1:1, 1X B27, 1X N2, and 1% L-glutamine
(all Gibco), 10 μM SB 431542 and 0.1 μM LDN 193189 (both
Selleckchem). Cells were ﬁxed for immunocytochemistry on day 21.
ICC analysis was performed with the antibodies against TUJ1, SMA and
AFP (Table 1).
2.6. Immunostaining of pluripotency genes
Cells were seeded on matrigel-coated coverslips. After 2 days, the
cells were ﬁxed at room temperature with 4% paraformaldehyde in
PBS for 10 min, permeabilized with 0.1% Triton X-100 and blocked for
unspeciﬁc bindingwith 2% BSA in PBS for 1 h. Immunostainingwas per-
formed with primary antibodies against OCT4, NANOG, TRA-1-60, TRA-
1-81, and SSEA4 (Table 1). After incubation with the primary antibody,
the cells were washed 3 times with PBS and then incubated with ﬂuo-
rescence-conjugated secondary antibodies Alexa ﬂuor 488 (goat anti-
mouse, 1:1000) or Cyanine 3 (goat anti-rabbit, 1:1000) for 1 h (both
Life technologies). The cells were mounted on glass slides with mount-
ing solution-containing DAPI (Life Technologies).2.7. Veriﬁcation and authentication
An intact genome was demonstrated by karyotyping using G-
banding of 12 mitoses (Fig. 1F). Analysis was performed at the Institute
of Medical Genetics and Applied Genomics, University of Tübingen,
Germany.
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